Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays
Annals of Laboratory Medicine
; : 195-209, 2024.
Article
in En
| WPRIM
| ID: wpr-1042033
Responsible library:
WPRO
ABSTRACT
Circulating tumor DNA (ctDNA) has emerged as a promising tool for various clinical applications, including early diagnosis, therapeutic target identification, treatment response monitoring, prognosis evaluation, and minimal residual disease detection. Consequently, ctDNA assays have been incorporated into clinical practice. In this review, we offer an indepth exploration of the clinical implementation of ctDNA assays. Notably, we examined existing evidence related to pre-analytical procedures, analytical components in current technologies, and result interpretation and reporting processes. The primary objective of this guidelines is to provide recommendations for the clinical utilization of ctDNA assays.
Full text:
1
Index:
WPRIM
Language:
En
Journal:
Annals of Laboratory Medicine
Year:
2024
Type:
Article